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leading role in respiratory symptoms. The
total IgE serum level was elevated
(1286 IU/ml) and the evaluation of serum-
speciﬁc IgE conﬁrmed the skin test results
(Bioallergy Italy).
The patient refused to consent to a
CSF analysis.
Our clinical and neuroimaging data
seem to be consistent with a diagnosis
of AM, although a sure diagnostic
statement is not available. Atopic myel-
itis should be considered in patients with
atopic dermatitis and respiratory allergy
in conjunction with neurological symp-
toms. Further studies will be necessary to
determine the diagnosis of this disease, its
prevalence in western countries, and the
mechanisms linking allergic and central
nervous system diseases.
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Cow’s milk allergy (CMA) is one of the
most frequent food allergies in the pedi-
atric popula-
tion. At our
outpatient
clinic its inci-
dence has
been increas-
ing over the
years, cow’s
milk being the
major food allergen implicated in chil-
dren (46% of the cases) (1).
The CMA is usually a transient con-
dition in which over 80% of the children
reach clinical tolerance before 3 years
of age; when it lasts longer than
36 months we deﬁne it as persistent. The
CMA has been pointed out as a marker
of a higher probability for developing
other allergic diseases, especially when it
persists (2, 3).
The aim of our study was to determine
the prevalence of other allergic diseases
in our CMA patients, to compare it
between two groups of children with
CMA of diﬀerent duration and also with
Figure 1. Nuclear magentic resonance (NMR) image of central nervous system (CNS) showing the
myelitis-like lesion.
Cow's milk allergy (CMA)
in childhood is a marker of
a high risk for subsequent
respiratory allergy.
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data from the general pediatric popu-
lation.
From September to November 2002,
we included a group of 76 children
followed up in our department with past
or present history of immunoglobulin
(Ig)E-mediated CMA, observed within
that period. The diagnosis was based on a
suggestive clinical history plus positive
skin prick tests and/or serum-speciﬁc IgE
to cow’s milk proteins, and conﬁrmed by
oral food challenges. The clinical toler-
ance was assessed by serial challenges
(every 6 months until 3 years of age;
annually afterwards). These children
were divided into two groups, according
to the duration of CMA: A – transient:
24 months or less; B – persistent: more
than 36 months.
The children were submitted to a
clinical reevaluation, and a questionnaire
(adapted from the International Study of
Asthma and Allergies in Childhood
(ISAAC) considering the presence of
allergic symptoms in the previous
12 months, was applied to all. Prevalence
from the general pediatric population
were obtained from ISAAC study (data
on ﬁle), regarding a randomized sample
of 2484 children, 6–7 years of age, living
in Lisbon.
Both groups had a mean age of 8 years
(range: 5–11), the M/F ratios were 2.5/1
vs 1.4/1 and the mean duration of CMA
was 10.8 (2–24) vs 80.1 (36–150) months
in groups A and B, respectively. Muco-
cutaneous symptoms (urticaria, angi-
oedema) were the most common clinical
manifestations in both groups
(A – 89%, B – 94%).
Table 1 shows and compares the
prevalence of other allergic diseases in
both groups and in the general pediatric
population (chi-square test, Yates
corrected, was used to analyze the
results).
Our results show that children with
CMA, regardless of its duration, have a
higher risk of developing respiratory
allergy compared with the general pedi-
atric population; and those with persis-
tent CMA have a higher prevalence of
asthma than the ones with the transient
condition, showing a trend for statistical
signiﬁcance. Atopic dermatitis was signi-
ﬁcantly more prevalent in the group with
CMA than in the general pediatric pop-
ulation, namely in those children with a
persistent condition.
These ﬁndings stress the importance of
a regular follow up of the children with
CMA and even raise the question whe-
ther primary preventive measures should
be considered, given their high risk for
subsequent respiratory allergy.
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Tagatose is a new food ingredient being
used as a reduced-calorie sweetener in
foods and bever-
ages. Tagatose is
a six-carbon ke-
tose sugar found
naturally in
some dairy
products and in tropical date trees. As
tagatose is incompletely absorbed, it
provides only 1.5 cal/g as contrary to
4 cal/g for sucrose. Tagatose has
approximately the same sweetness as
sucrose. Recently, a manufacturing
process for tagatose has been developed
allowing the production of increased
quantities of tagatose. Tagatose has
been aﬃrmed as Generally Recognized
as Safe (GRAS) in the US and is
approved for use in foods and beverages
in the US, Korea, Australia and New
Zealand.
Tagatose is a unique ketose sugar
manufactured by the isomerization of
galactose. The galactose involved in the
manufacturing of tagatose is derived
from lactose, the disaccharide found in
the whey fraction of milk. Lactose is
known to contain residual milk proteins
including several of the major cows milk
allergens, principally b-lactoglobulin and
a-lactalbumin from whey, on occasion
(1). Consequently, some questions were
raised about the potential allergenicity of
tagatose.
Although lactose often contains resid-
ual milk allergens, tagatose is much less
likely to contain any milk allergens based
upon knowledge of the process used to
Tagatose does not
contain milk residues.
Table 1. Prevalence of other allergic diseases in group A, group B and general pediatric population (ISAAC)
A + B
(n ¼ 76, %)
A
(n ¼ 45, %)
B
(n ¼ 31, %)
ISAAC
(n ¼ 2484, %)
A vs B
(P-value)
A + B vs ISAAC
(P-value)
A vs ISAAC
(P-value)
B vs ISAAC
(P-value)
Asthma 45 36 58 14 0.05 <0.0001 <0.0001 <0.0001
Rhinitis 41 40 42 26 0.84 0.004 0.03 0.04
Atopic dermatitis 29 22 39 15 0.11 0.001 0.19 0.0003
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